Axsome Therapeutics (AXSM) Change in Accured Expenses (2015 - 2026)

Axsome Therapeutics (AXSM) has 12 years of Change in Accured Expenses data on file, last reported at $17.2 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses rose 2006.23% year-over-year to $17.2 million; the trailing twelve-month figure through Mar 2026 stood at $100.2 million (up 53.38% YoY), and the FY2025 full-year result was $83.7 million, up 49.37% from the prior year.
• Change in Accured Expenses rose to $17.2 million in Q1 2026, from $7.2 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $54.2 million in Q3 2025 to a low of -$8.4 million in Q1 2024.
• A 5-year average of $14.0 million and a median of $11.4 million in 2023 frame the typical range for Change in Accured Expenses.
• Across the five-year window, Change in Accured Expenses surged 8238.14% in 2022 and plunged 217.81% in 2024, its largest moves.
• Tracing AXSM's Change in Accured Expenses over 5 years: stood at $13.2 million in 2022, then dropped by 13.91% to $11.4 million in 2023, then soared by 125.95% to $25.7 million in 2024, then sank by 72.05% to $7.2 million in 2025, then soared by 140.16% to $17.2 million in 2026.
• Business Quant data shows AXSM's Change in Accured Expenses at $17.2 million in Q1 2026, $7.2 million in Q4 2025, and $54.2 million in Q3 2025.